|
2026
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for t... |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
|
Invention
|
Polq inhibitors.
The specification generally relates to compounds of Formula (I):
The specific... |
|
|
Invention
|
Graph construction and visualization of multiplex immunofluorescence images.
Example techniques ... |
|
|
Invention
|
Unit dose comprising anti-ccr9 antibody. Unit doses of the anti-CCR9 antibody AZD7798 and their u... |
|
|
Invention
|
Combination therapies for the treatment of cancer. Provided are methods of treating cancer, such ... |
|
|
Invention
|
Heteroaromatic compounds. The specification relates to compounds of Formula (I): (I) and to pharm... |
|
|
Invention
|
Conjugates. The present disclosure relates to conjugates and drug conjugates comprising an acid-l... |
|
|
Invention
|
Dosage regimens for the administration of antibody drug conjugates. This disclosure relates to do... |
|
|
Invention
|
Antibody-drug conjugates. The present invention relates to anti-CD30 antibody-drug conjugates and... |
|
|
Invention
|
Antibody-drug conjugates. The present invention relates to conjugates comprising an antibody or a... |
|
|
Invention
|
Capivasertib for use in the treatment of pten hamartoma tumor syndrome. Described herein are meth... |
|
|
Invention
|
Carboxamide compounds. Compounds having the structure of Formula (1): and pharmaceutically accept... |
|
|
Invention
|
Fused pyrimidine compounds as kcc2 modulators.
The invention concerns compounds of Formula (I):
... |
|
|
Invention
|
Combination therapies for treatment of cancer. Provided herein are methods of treating cancer in ... |
|
|
Invention
|
Antibody drug conjugates comprising two glucuronic acid linkers to treat her2 cancers. The specif... |
|
|
Invention
|
Cd8-binding cytokine engager combination therapies. The disclosure provides methods of treating c... |
|
|
Invention
|
Conjugates comprising cleavable linkers. The specification relates to conjugates comprising one o... |
|
|
Invention
|
Ras inhibitors with a tricyclic core. The present specification relates to compounds, and pharmac... |
|
|
Invention
|
Conjugates comprising cleavable linkers. The specification relates to a compound of Formula (I) a... |
|
|
Invention
|
Conjugates comprising cleavable linkers. The specification relates to conjugates comprising a lin... |
|
|
Invention
|
Oral formulation of a therapeutic compound.
The present invention provides a pharmaceutical tabl... |
|
|
Invention
|
Targeted lipid nanoparticles. Lipid nanoparticles are provided which comprise a lipid matrix and ... |
|
|
Invention
|
7-fluoro-5-methoxy-2,3-dihydro-[1,3]oxazino[4,5,6-de]quinazoline derivatives as ras g12d inhibito... |
|
2025
|
Invention
|
Heterocyclic inhibitors of ripk1. The present specification relates to compounds of formula (I) w... |
|
|
Invention
|
Dry powder inhaler. There is described herein a dry powder inhaler device (100) for administering... |
|
|
Invention
|
Crystalline forms of 6'-([(1s, 3s)-3-([difluoromethoxy)- 2-pyrimidinyl]amino)cyclopentyl]amino)-2... |
|
|
Invention
|
Biliary tract cancer treatment with anti-claudin 18.2 adc.
Provided herein is a method of treati... |
|
|
Invention
|
Biliary tract cancer treatment with anti-claudin 18.2 adc. Provided herein is a method of treatin... |
|
|
Invention
|
Smarca2 degraders and uses thereof. The present disclosure provides compounds represented by Form... |
|
|
Invention
|
Dosing regimen for the treatment of fap-mediated conditions. The present disclosure relates to me... |
|
|
Invention
|
Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and co... |
|
|
Invention
|
Pharmaceutical formulations.
The present specification relates to pharmaceutical formulations co... |
|
|
Invention
|
Anti-il5r antibody formulations.
Provided herein are anti-IL5R antibody formulations containing ... |
|
|
Invention
|
Amido heteroaromatic compounds.
The specification relates to compounds of Formula (1):
The spe... |
|
2024
|
Invention
|
Treatment of non-small cell lung cancer.
The disclosure generally relates to methods and composi... |
|
|
Invention
|
Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer.
A method... |
|
|
Invention
|
Combinations of kras inhibitor and atr inhibitor for the treatment of cancer.
The present provid... |
|
|
Invention
|
Fluidic mixer unit device for nanoparticle production.
A device 100 for producing nanoparticles ... |
|
|
Invention
|
Use of inhibitors to increase efficiency of crispr/cas insertions.
The present disclosure provid... |
|
|
Invention
|
Compounds and their use in treating cancer.
A compound of Formula (I): or a pharmaceutically acc... |
|
|
Invention
|
Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof.
Th... |
|
2023
|
Invention
|
Nlrp3 inflammasome inhibitors.
The specification generally relates to compounds of Formula (I), ... |
|
|
Invention
|
Cancer therapy with capivasertib and fulvestrant.
The present disclosure relates to therapeutic ... |
|
|
Invention
|
Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg.... |
|
|
Invention
|
Combinations of a serd for the treatment of cancer.
The present specification relates a method o... |
|
|
Invention
|
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatm... |
|
|
Invention
|
Solid forms of rxfp1 modulators.
The specification generally relates to solid forms, for example... |
|
|
Invention
|
Gene therapy compositions and methods of use thereof.
Presented herein are compositions and meth... |
|
2021
|
Invention
|
Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies... |
|
2020
|
Invention
|
Modulators of pnpla3 expression.
The present embodiments provide methods, compounds, and composi... |
